The multidisciplinary Blom Research Group, Faculty of Medicine, Lund University is recruiting two postdoctoral fellows with appropriate training and publication-documented expertise to work on one of the two projects, one focused on cancer and the other – infections.
The group’s homepage:
The successful applicants will join one of the two ongoing projects:
The first one is focused on understanding the molecular mechanism behind function of Cartilage Oligomeric Matrix Protein (COMP) as a common cancer promotor. Expression of COMP is strongly associated with poor patient prognosis and metastases in several types of cancer such as breast, prostate, colon, pancreatic and ovarian cancer. We have identified several potential mechanisms by which COMP is exerting its action and these will be now studied on cellular and protein levels. Further, the project will address clinical relevance of COMP expression for prognostication and resistance to chemotherapy.
The second project is focused on the role of the main complement factor C3 in the antibacterial responses. The novelty of the project lies in the study of intracellular roles of C3 as opposed to its well established anti-bacterial functions in blood. Additionally, the project aims to identity evasions strategies developed by some bacterial pathogens to avoid intracellular C3 responses.
The collaborative project will offer an excellent opportunity for training in a wide range of advanced methods. These include advanced flow cytometry, confocal and superresolution microscopy, molecular techniques including CRISP/Cas-9 gene editing, protein interactions and cancer/microbiology specific assays. There will be opportunity to learn cancer animal models depending on the candidate’s interest. In addition, recruited fellow will participate in high standard scientific meetings presenting their work, and in collaboration with prestigious scientists, and clinical partners in fields of oncology and pathology.
Our research group focuses on the innate immunity in physiology and pathology including cancer and infections. We offer challenging project, which involves state-of-the-art instrumentation, and great educational opportunities in a dynamic and multidisciplinary research group with high reputation and collegial work culture. Importantly, the successful candidate will work closely with the group leader in collaborative research setting to develop the project and support the candidate in achieving their career goals.
Lund University and vicinity
Lund University, located in southern Sweden is repeatedly ranked among the world’s top 100 universities. The University has 40 000 students and more than 8 000 staff based in Lund, Helsingborg and Malmö. Our laboratory is located on the medical campus at Skåne University Hospital (SUS) in Malmö with good public transport to both Lund and Copenhagen (25 min to Copenhagen airport). The city is culturally diverse and offers a multitude of recreational opportunities within the city and in the nearby counties. Candidates do not need to acquire skills in Swedish language as most Swedes can easily communicate in English.
The candidate must hold a PhD in the field of preferentially cancer research (project 1), microbiology (project 2) or for both projects: immunology, cell biology or related discipline, and must have completed their PhD within 3 years from the start of the appointment.
Previous experience in all or some of the following: cancer research (project 1), microbiology (project 2) and for both projects: cell biology, protein expression and analysis, flow cytometry, microscopy, and statistical analyses are advantageous.
Applicants should be highly motivated, able to work both independently and in collaboration, inventive and communicative.
Fluency in both written and spoken English is mandatory.
Candidates should send their application by e-mail to prof. Anna Blom (email@example.com). Make sure to include curriculum vitae, publication list and e-mail address of two references. The deadline December 26th 2021.
Starting date is flexible. The position is funded for 2 years with tax-free stipend of 26 000 sek/month (approx. 2450 euro/month)
Selected recent publications from the group relevant to the two projects
Englund E., Bartoschek M., Reitsma B., Jacobsson L., Escudero-Esparza A., Orimo A., Leandersson K., Hagerling C., Aspberg A., Storm P., Okroj M., Mulder H., Jirström K., Pietras K., and Blom A.M. (2016) Cartilage Oligomeric Matrix Protein (COMP) contributes to the development and metastasis of breast cancer., Oncogene, 35, 5585-5596.
Englund E., Canesin G., Papadakos K.S., Vishnu N., Persson E., Reitsma B., Anand A., Jacobsson L., Helczynski L., Mulder H., Bjartell A. and Blom A.M. (2017) Cartilage Oligomeric Matrix Protein promotes prostate cancer progression by enhancing invasion and disrupting calcium homeostasis., Oncotarget, 8, 98298-98311.
Papadakos K.S., Bartoschek M., Rodriguez C., Gialeli C., Jin S., Lendahl U., Pietras K., and Blom A.M. (2019) Cartilage Oligomeric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling., Matrix Biology, 81, 107-121.
King B.C., Kulak K., Krus U., Rosberg R., Golec E., Wozniak K., Gomez M.F., Zhang E., O’Connell D., Renström E., and Blom A.M. (2019) Complement C3 protects against autophagy related b-cell death via ATG16L1 interaction and regulation of autophagy., Cell Metabolism, 29, 202-210.
Ermert D., Shaughnessy J., Joeris T., Kaplan J., Pang C. J., Kurt-Jones E. A., Rice P.A., Ram S. and Blom A. M. (2015) Virulence of group A streptococci is enhanced by human complement inhibitors., PLOS Pat, 11, e1005043.
Potempa M., Potempa J., Kantyka T., Nguyen K., Wawrzonek K., Manandhar S., Popadiak K., Riesbeck K., Eick S. and Blom A. M. (2009) Interpain, cysteine proteinase from Prevotella intermedia inhibits complement by degrading complement factor C3., PLOS Pathogens, 5, e1000316